Ligand Pharmaceuticals (LGND) EBT Margin Growth (3y) (2013 - 2026)

Ligand Pharmaceuticals (LGND) EBT Margin Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 9,237.00
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 441.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -408.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 363.00
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Ligand Pharmaceuticals 6.05 Bn 5.27 Bn 48.45 Mn -17,318.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -17,318.00
Dec 31, 2025 4,725.00
Sep 30, 2025 10,138.00
Jun 30, 2025 629.00
Mar 31, 2025 -8,565.00
Dec 31, 2024 -12,326.00
Sep 30, 2024 -3,780.00
Jun 30, 2024 -19,968.00
Mar 31, 2024 35,385.00
Dec 31, 2023 3,912.00
Sep 30, 2023 -920.00
Jun 30, 2023 -5,586.00
Mar 31, 2023 21,800.00
Dec 31, 2022 7,819.00
Sep 30, 2022 10,096.00
Jun 30, 2022 8,943.00
Mar 31, 2022 -196,303.00
Dec 31, 2021 12,700.00
Sep 30, 2021 -14,794.00
Jun 30, 2021 -6,392.00